Enveric Biosciences Company Insiders

ENVB Stock  USD 2.10  0.08  3.96%   
Enveric Biosciences employs about 5 people. The company is managed by 6 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 0.83 employees per reported executive. Analysis of Enveric Biosciences' management performance can provide insight into the company performance.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

Enveric Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Enveric Biosciences' future performance. Based on our forecasts, it is anticipated that Enveric will maintain a workforce of about 30 employees by March 2026.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Enveric Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (1.2973) % which means that it has lost $1.2973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6196) %, meaning that it created substantial loss on money invested by shareholders. Enveric Biosciences' management efficiency ratios could be used to measure how well Enveric Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 17, 2026, Return On Tangible Assets is expected to decline to -3.8. The current year's Return On Capital Employed is expected to grow to -6.61. At present, Enveric Biosciences' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 4.2 M, whereas Total Assets are forecasted to decline to about 3.4 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 50.6 K, whereas Net Loss is projected to grow to (41.9 M). Roughly 92.55 percent of Enveric Biosciences outstanding shares are held by general public with 0.52 (percent) owned by insiders and only 6.93 % by other corporate entities.
 
Shares in Circulation  
First Issued
1993-09-30
Previous Quarter
216.3 K
Current Value
313.2 K
Avarage Shares Outstanding
16.4 K
Quarterly Volatility
45.7 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as Enveric Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Enveric Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Enveric Biosciences Workforce Comparison

Enveric Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 121. Enveric Biosciences holds roughly 5.0 in number of employees claiming about 4% of equities under Health Care industry.

Enveric Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enveric Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enveric Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enveric Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2018-12-01
0.0263
1
38
 150,000 
 400,000 
2018-09-01
3.5
14
4
 3,956,115 
 3,477,987 
2018-06-01
1.0
1
1
 25,000 
 329,357 
2018-03-01
1.75
14
8
 351,875 
 135,842 
2017-12-01
4.0
12
3
 973,691 
 335,763 
2017-09-01
4.0
4
1
 1,226,218 
 1,666,666 
2017-06-01
6.8333
41
6
 319,564 
 16,147 
2017-03-01
23.0
23
1
 179,575 
 0.00 
2016-12-01
17.0
17
1
 367,288 
 0.00 
2016-06-01
4.3333
26
6
 3,146,253 
 1,211,111 
2015-06-01
1.0
4
4
 2,782,778 
 0.00 
2005-12-01
1.0
1
1
 11,304 
 633.00 
2003-12-01
0.1481
4
27
 550,000 
 460,000 

Enveric Biosciences Notable Stakeholders

An Enveric Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enveric Biosciences often face trade-offs trying to please all of them. Enveric Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enveric Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph TuckerCEO DirectorProfile
Ibrahim MDChief OfficerProfile
MBA IVInterim OfficerProfile
Peter FacchiniChief OfficerProfile
Avani KanubaddiPres COOProfile
Kevin CPAChief OfficerProfile
String symbol = request.getParameter("s");

About Enveric Biosciences Management Performance

The success or failure of an entity such as Enveric Biosciences often depends on how effective the management is. Enveric Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enveric management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enveric management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(3.62)(3.80)
Return On Capital Employed(6.95)(6.61)
Return On Assets(3.57)(3.75)
Return On Equity(6.91)(6.57)
Please note, the presentation of Enveric Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enveric Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enveric Biosciences' management manipulating its earnings.

Enveric Biosciences Workforce Analysis

Traditionally, organizations such as Enveric Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enveric Biosciences within its industry.

Enveric Biosciences Manpower Efficiency

Return on Enveric Biosciences Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.9M
Net Loss Per Executive1.6M
Working Capital Per Employee249K
Working Capital Per Executive207.5K

Complementary Tools for Enveric Stock analysis

When running Enveric Biosciences' price analysis, check to measure Enveric Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enveric Biosciences is operating at the current time. Most of Enveric Biosciences' value examination focuses on studying past and present price action to predict the probability of Enveric Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enveric Biosciences' price. Additionally, you may evaluate how the addition of Enveric Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data